Millennium Management
CLRB icon

Millennium Management’s Cellectar Biosciences CLRB Stock Holding History

Millennium Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,422
Closed -$107K – 6137
2024
Q2 		$107K Buy
+1,422
New +$136K ﹤0.01% 5298
2021
Q2 		– Sell
-822
Closed -$397K – 6577
2021
Q1 		$397K Buy
822
+761
+1,248% +$452K ﹤0.01% 5009
2020
Q4 		$38K Buy
+61
New +$28K ﹤0.01% 5102
2020
Q3 		– Sell
-47
Closed -$18K – 4486
2020
Q2 		$18K Buy
+47
New +$19.7K ﹤0.01% 4098

Other funds holding CLRB

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management's CLRB Position: Q3 2024 in Review

Millennium Management sold out of Cellectar Biosciences (CLRB) in Q3 2024, closing a stake of 1,422 shares — an estimated $107K sold.

Millennium Management first reported a position in CLRB in Q2 2020 and held it in 4 quarters. The position peaked at $397K in Q1 2021. 35 funds tracked by Wall St. Rank hold CLRB as of Q3 2024.

  • Millennium Management reported no remaining Cellectar Biosciences position as of Q3 2024 after selling out during the quarter.
  • Millennium Management sold 1,422 Cellectar Biosciences shares in Q3 2024, an estimated $107K.
  • Millennium Management first reported a position in Cellectar Biosciences in Q2 2020 and held it in 4 quarters.
  • Millennium Management's Cellectar Biosciences position peaked at $397K in Q1 2021.
  • 35 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2024.

Based on Millennium Management's 13F filing for Q3 2024, filed 14 Nov 2024.